PTC Therapeutics, Inc. (PTCT) News
Track canonical SquawkNews coverage tagged to PTCT, PTC Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 23 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
PTCT: Sephience’s robust launch and global expansion drive raised guidance and pipeline momentum
Sephience’s launch is outperforming prior PKU therapies, driving raised revenue guidance and strong global expansion. Real-world data confirm broad patient benefit, while pipeline programs advance in Friedreich ataxia, H
EARNINGS | Sep 15, 2026, 03:41 PM UTC
H
PTCT: Sephience’s strong launch and global expansion drive raised guidance and future growth
Sephience’s launch is outperforming prior PKU therapies, driving raised revenue guidance and global expansion. Real-world and clinical data reinforce its broad applicability, while pipeline progress and a strategic acqui
EARNINGS | Sep 15, 2026, 02:27 PM UTC
L
PTC Therapeutics Price Target Announced at $98.00/Share by Leerink Partners
Ratings actions from Benzinga
NEWS | Sep 14, 2026, 09:07 PM UTC
L
PTCT: Broad PKU launch, strong pipeline, and global expansion drive growth and profitability
Management highlighted strong financials, broad PKU launch success, and a robust rare disease pipeline. International growth is expected to accelerate from 2026, with strategic pricing and reimbursement efforts underway.
EQUITY | Sep 10, 2026, 03:00 PM UTC
L
PTCT: Global rare disease growth driven by SUFIANCE, new assets, and disciplined financial strategy
Management highlighted strong financial positioning, global expansion of SUFIANCE, and a robust rare disease pipeline. Key growth drivers include international launches, new gene therapy assets, and disciplined operation
EQUITY | Sep 10, 2026, 02:33 PM UTC
L
PTC Therapeutics to buy drug candidate from Sangamo for up to $211M
PTC Therapeutics plans to buy a drug candidate from Sangamo for up to $211M.
EQUITY | Aug 28, 2026, 09:59 PM UTC
L
PTC Therapeutics to make $111M upfront payment, with up to $100M milestones
PTC Therapeutics will make an upfront payment of $111 million and may pay up to an additional $100 million in contingent milestone payments.
EQUITY | Aug 28, 2026, 09:42 PM UTC
M
PTC Therapeutics agrees to acquire Sangamo ST-920 Fabry assets
PTC Therapeutics agreed to acquire Sangamo assets primarily related to ST-920, an AAV gene therapy product candidate for Fabry disease.
MNA | Aug 28, 2026, 09:42 PM UTC
L
PTC Therapeutics enters asset purchase agreement with Sangamo
PTC Therapeutics entered into an asset purchase agreement with Sangamo Therapeutics.
EQUITY | Aug 28, 2026, 09:42 PM UTC
M
PTC Therapeutics to buy ST-920 Fabry gene therapy for $111M
PTC Therapeutics agreed to buy Sangamo’s ST-920 Fabry gene therapy for $111M, with $100M in milestones.
EQUITY | Aug 28, 2026, 08:15 PM UTC
L
PTCT - PTC Therapeutics to Participate in Upcoming Investor Conferences
PTCT - PTC Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Aug 27, 2026, 12:02 PM UTC
L
PTC Therapeutics presents new Sephience data
PTC Therapeutics says new Sephience (sepiapterin) data reinforce sustained metabolic control, diet liberalization and a consistent favorable safety profile.
EQUITY | Aug 24, 2026, 12:01 PM UTC
M
PTC Therapeutics plans ST-920 Fabry program acquisition
PTC Therapeutics says it will acquire Sangamo Therapeutics’ ST-920 Fabry disease program in a competitive bankruptcy auction for $111 million upfront plus up to $100 million in contingent milestone payments.
MNA | Aug 13, 2026, 04:28 PM UTC
H
PTC Therapeutics Acquires ST-920 Fabry Disease Program
PTC Therapeutics is acquiring the BLA-stage ST-920 Fabry disease program for $111M upfront and up to $100M in contingent milestone payments
MNA | Aug 12, 2026, 08:14 PM UTC
H
PTC Expands Rare Disease Portfolio
PTC acquires BLA-stage ST-920 Fabry disease program
MNA | Aug 12, 2026, 08:02 PM UTC
L
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength o
EARNINGS | Aug 04, 2026, 10:04 AM UTC
H
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:34 PM UTC
H
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after resu
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:18 PM UTC
L
PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B Est
PTC Therapeutics (NASDAQ: PTCT ) raises FY2026 sales outlook from $1.080 billion-$1.180 billion to $1.180 billion-$1.280 billion vs $1.196 billion estimate.
EARNINGS | Jul 30, 2026, 08:05 PM UTC
H
PTCT PTC Therapeutics RESULTS: Q2, Q2 product REV $238,819,238.819M, Q2 operating expenses $211.542M, Q2 Net Income $83.496M, Q2 Operating I
PTCT PTC Therapeutics RESULTS: Q2, Q2 product REV $238,819,238.819M, Q2 operating expenses $211.542M, Q2 Net Income $83.496M, Q2 Operating Income $148.977M, Q2 basic EPS $1.01, PTC Therapeutics Earnings Notes:, Outlook F
EARNINGS | Jul 30, 2026, 08:02 PM UTC
L
PTCT PTCT - PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PTCT PTCT - PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 30, 2026, 08:01 PM UTC
L
PTCT Reiterate Overweight and $120 PT - continue to have high conviction in shares and see the PKU global opportunity as underappreciated @
PTCT Reiterate Overweight and $120 PT - continue to have high conviction in shares and see the PKU global opportunity as underappreciated @ BARC
EQUITY | Jul 21, 2026, 12:10 PM UTC
H
PTC Therapeutics price target raised to $85 from $82 at RBC Capital
RBC Capital raised the firm's price target on PTC Therapeutics to $85 from $82 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has
RATES | Jul 07, 2026, 11:22 AM UTC